Transition Therapeutics to Pay Eli Lilly $1M

NEW YORK ( TheStreet) -- Biopharmaceutical company Transition Therapeutics ( TTHI) is set to pay Eli Lilly ( LLY) $1 million to acquire exclusive rights to develop and potentially commercialize a series of preclinical compounds for diabetes, which could later be more than recouped if Lilly decides to reacquire these rights.

Eli Lilly will be receiving an upfront payment of $1 million and will retain the option to reacquire the rights to the compounds at a later date. If Lilly decides to exercise these rights, Transition would be eligible to receive about $250 million in payments and up to low double digit royalties on sales of products containing such compounds if they're successfully commercialized.

If Lilly does not exercise these rights, Lilly would be eligible for low single digit royalties from Transition on sales of products containing such compounds should such products be successfully commercialized.

Transition Therapeutics ended Tuesday's trading session at $2.60, down 2.6%, but has risen 1.7% to $2.70 in pre-market trading. Meanwhile Lilly finished Tuesday 0.7% higher at $34.60.

-- Reported by Andrea Tse in New York

Follow TheStreet.com on Twitter and become a fan on Facebook.

Copyright 2009 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

More from Stocks

Dropbox Is the New Defensive Stock to Own With the Market Falling Apart

Dropbox Is the New Defensive Stock to Own With the Market Falling Apart

Dow Sells Off as U.S. and China Trade Tensions Escalate

Dow Sells Off as U.S. and China Trade Tensions Escalate

The Quick Answer Why Trump's Trade War Makes Stocks at Least 10% Overvalued

The Quick Answer Why Trump's Trade War Makes Stocks at Least 10% Overvalued

China Central Bank Governor Says Stay 'Calm and Rational' After Market Free Fall

China Central Bank Governor Says Stay 'Calm and Rational' After Market Free Fall

Marriott CEO on Tax Cuts, Trade War Worries and China's Economy

Marriott CEO on Tax Cuts, Trade War Worries and China's Economy